Infant Bacterial Therapeutics AB (FRA:9IB) Tariff Resilience Score: 0/10 (As of Jul. 04, 2026)


FRA:9IB Infant Bacterial Therapeutics AB FRA:9IB
13 GF Score
Price €6.29
! 2 Warning Signs
View Full Analysis

What is Infant Bacterial Therapeutics AB Tariff Resilience Score?

Infant Bacterial Therapeutics AB has the Tariff Resilience Score of 0, which implies that the company might have .

Infant Bacterial Therapeutics AB has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Infant Bacterial Therapeutics AB might have .

Infant Bacterial Therapeutics AB  (FRA:9IB) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Infant Bacterial Therapeutics AB Tariff Resilience Score Related Terms

FRA:9IB
13GF Score
Infant Bacterial Therapeutics AB FRA:9IB
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Infant Bacterial Therapeutics AB Business Description

Other Exchanges IBT B:Sweden
Address Katarina Bangata 70, Stockholm, SWE, 116 42
Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance, Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118, and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.
13GF Score

Get the complete analysis for FRA:9IB

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.29
Price